publication date: Jan. 25, 2017
January 2017 PDF
Prostate Cancer Study Shows Only Nuclear-Localized AR-V7 Predictive of Benefit for Patients with Metastatic Disease
Investigators from Memorial Sloan Kettering Cancer Center and Epic Sciences published findings in European Urology that only nuclear localization of AR-V7 protein in circulating tumor cells from metastatic castration-resistant prostate cancer patient blood samples is predictive of therapeutic benefit.
Pediatric Cancers Early-phase Study Shows Shrinkage in Pediatric Neural Tumors
In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage. NF1 affects one in 3,000 people.
Breast Cancer MammaPrint Substantially Impacts How Breast Cancer in Germany is Treated
Agendia Inc. has presented new prospective data demonstrating the strong impact of its 70-Gene Breast Cancer Recurrence Assay, MammaPrint, and the corresponding 80-Gene Molecular Subtyping Assay BluePrint, in clinical decision-making for patients with early-stage breast cancer in Germany.
Merrimack … Continue reading CCL Jan 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.